FDA hits Novartis with unexpected 3-month delay on MS drug ofatumumab

FDA hits Novartis with unexpected 3-month delay on MS drug ofatumumab

Last week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofis Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which wa…
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *